Compare Procter & Gamble Health with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs AUROBINDO PHARMA - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH AUROBINDO PHARMA PROCTER & GAMBLE HEALTH/
AUROBINDO PHARMA
 
P/E (TTM) x 53.0 9.4 567.2% View Chart
P/BV x 4.6 1.7 267.2% View Chart
Dividend Yield % 10.3 0.6 1,685.2%  

Financials

 PROCTER & GAMBLE HEALTH   AUROBINDO PHARMA
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
AUROBINDO PHARMA
Mar-19
PROCTER & GAMBLE HEALTH/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs3,549830 427.6%   
Low Rs1,301527 246.9%   
Sales per share (Unadj.) Rs511.4333.9 153.2%  
Earnings per share (Unadj.) Rs61.340.4 151.9%  
Cash flow per share (Unadj.) Rs74.051.8 143.0%  
Dividends per share (Unadj.) Rs440.002.50 17,600.0%  
Dividend yield (eoy) %18.10.4 4,924.4%  
Book value per share (Unadj.) Rs927.8237.1 391.3%  
Shares outstanding (eoy) m16.60585.91 2.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.72.0 233.3%   
Avg P/E ratio x39.616.8 235.3%  
P/CF ratio (eoy) x32.813.1 249.9%  
Price / Book Value ratio x2.62.9 91.3%  
Dividend payout %717.96.2 11,588.8%   
Avg Mkt Cap Rs m40,257397,569 10.1%   
No. of employees `0001.117.9 6.4%   
Total wages/salary Rs m1,31325,849 5.1%   
Avg. sales/employee Rs Th7,486.710,956.9 68.3%   
Avg. wages/employee Rs Th1,157.61,447.7 80.0%   
Avg. net profit/employee Rs Th897.21,324.3 67.7%   
INCOME DATA
Net Sales Rs m8,490195,636 4.3%  
Other income Rs m2441,553 15.7%   
Total revenues Rs m8,734197,189 4.4%   
Gross profit Rs m1,48239,519 3.7%  
Depreciation Rs m2116,680 3.2%   
Interest Rs m02,626 0.0%   
Profit before tax Rs m1,51431,767 4.8%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m66-881 -7.4%   
Tax Rs m5637,269 7.7%   
Profit after tax Rs m1,01723,645 4.3%  
Gross profit margin %17.520.2 86.4%  
Effective tax rate %37.122.9 162.3%   
Net profit margin %12.012.1 99.2%  
BALANCE SHEET DATA
Current assets Rs m15,343153,645 10.0%   
Current liabilities Rs m1,960120,429 1.6%   
Net working cap to sales %157.617.0 928.4%  
Current ratio x7.81.3 613.5%  
Inventory Days Days49135 36.0%  
Debtors Days Days2864 44.7%  
Net fixed assets Rs m1,209103,909 1.2%   
Share capital Rs m166586 28.3%   
"Free" reserves Rs m15,235138,322 11.0%   
Net worth Rs m15,401138,908 11.1%   
Long term debt Rs m01,800 0.0%   
Total assets Rs m17,595264,544 6.7%  
Interest coverage xNM13.1-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.7 65.2%   
Return on assets %5.89.9 58.2%  
Return on equity %6.617.0 38.8%  
Return on capital %10.323.8 43.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,63697,316 1.7%   
Fx outflow Rs m4,36840,589 10.8%   
Net fx Rs m-2,73256,727 -4.8%   
CASH FLOW
From Operations Rs m-1,30416,220 -8.0%  
From Investments Rs m12,697-28,768 -44.1%  
From Financial Activity Rs m-30119,191 -1.6%  
Net Cashflow Rs m11,0936,656 166.7%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 8.0 228.9%  
FIIs % 1.0 27.7 3.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 10.2 285.3%  
Shareholders   28,591 69,601 41.1%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  NOVARTIS  DR. DATSONS LABS  

Compare PROCTER & GAMBLE HEALTH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Nov 15, 2019 03:37 PM

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 5-YR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS